Tiny ht6nlyd2rhf3yxpl0wtk09eudgqrijbuqxdhp dtrvy

Katrine Bosley

Chief Executive Officer, Editas Medicine

Graduate, Cornell University. Twenty-five years’ experience in the biotechnology industry; has worked on innovative medicines across many different modalities (small molecules, biologics, vaccines, gene editing) and many different diseases (cancer, rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, rare genetic diseases, Hepatitis C, et al). Formerly: with Biogen in business development, commercial operations, and portfolio strategy; Member, Healthcare Team, Highland Capital Partners; Vice-President, Business Development, Adnexus Therapeutics; then Vice-President, Strategic Operations, after Adnexus’ acquisition by Bristol-Myers Squibb; Chief Executive Officer, Avila Therapeutics (acquired by Celgene); Entrepreneur-in-Residence, The Broad Institute, a biomedical and genomic research centre. Currently, Chief Executive Officer, Editas Medicine. Chairman of the Board, Genocea Biosciences. Member of the Board: Galapagos; Scholar Rock; BIO – the Biotechnology Industry Organization. Review Committee Member, Translation Fund, Wellcome Trust.